New AHA statement clarifies how to spot secondary Raynaud and manage severe disease

Clinical takeaway: Most patients with Raynaud phenomenon can be managed with trigger avoidance, warming strategies, and smoking cessation, but clinicians should actively look for features suggesting secondary disease, such as late onset, male sex, asymmetric symptoms, digital ulcers, thumb involvement, or signs of connective tissue disease. Dihydropyridine calcium channel blockers remain first-line drug therapy, with phosphodiesterase-5 inhibitors, fluoxetine, topical nitrates, and other vasodilators reserved for selected patients.

In its first scientific statement on Raynaud phenomenon, the American Heart Association reviews the diagnosis and management of both primary and secondary Raynaud, emphasizing the importance of distinguishing the generally benign primary form from secondary disease, which can lead to digital ischemia, ulceration, tissue loss, and amputation. The statement notes that secondary Raynaud is most commonly associated with systemic autoimmune diseases, particularly systemic sclerosis.

The authors highlight nailfold videocapillaroscopy (NVC) as a key tool for differentiating primary from secondary Raynaud. Normal capillary findings support a diagnosis of primary disease, whereas giant capillaries, microhemorrhages, and capillary dropout strongly suggest systemic sclerosis-related secondary Raynaud and may help identify disease at an earlier stage.

Lifestyle measures remain the foundation of treatment. Patients should be counseled on smoking cessation, avoidance of cold exposure, stress reduction, and minimizing vasoconstrictive substances such as nicotine, caffeine, cocaine, and amphetamine derivatives. The statement also urges clinicians to review medications that may worsen symptoms, including some β-blockers, sympathomimetic agents used for ADHD, and certain chemotherapies.

Among pharmacologic options, long-acting dihydropyridine calcium channel blockers such as amlodipine and nifedipine remain first-line therapy. Phosphodiesterase-5 inhibitors, including sildenafil and tadalafil, have also demonstrated benefit in reducing attack frequency and severity. For patients with low or normal blood pressure who may not tolerate vasodilators, fluoxetine is identified as a potential option. Topical nitrates may provide localized symptom relief, while IV prostanoids such as epoprostenol are reserved for severe digital ischemia. Aspirin may be considered in secondary Raynaud with digital ulceration or ischemia, though evidence remains limited.

The statement also reviews emerging but less-established approaches. Botulinum toxin type A injections have shown promise in treatment-refractory disease and digital ulcer healing, but inconsistent randomized trial results preclude routine use. Surgical sympathectomy and selected endovascular interventions may be considered for severe, refractory ischemic disease.

“Treating the underlying disease is essential to improving vascular symptoms and preventing complications in secondary Raynaud phenomenon,” the authors write, while emphasizing the need for earlier identification of high-risk patients and more robust clinical trials to guide therapy.

Source: Ujueta F, et al. (2026 Aug 25) Circulation. Primary and Secondary Raynaud: A Scientific Statement From the American Heart Association